Literature DB >> 15492226

TIFA activates IkappaB kinase (IKK) by promoting oligomerization and ubiquitination of TRAF6.

Chee-Kwee Ea1, Lijun Sun, Jun-Ichiro Inoue, Zhijian J Chen.   

Abstract

TRAF6 (tumor necrosis factor receptor-associated factor 6) is a RING (really interesting new gene) domain ubiquitin (Ub) ligase that mediates the activation of protein kinases, such as transforming growth factor beta-activated kinase (TAK1) and IkappaB kinase (IKK), by catalyzing the formation of a unique polyubiquitin chain linked through Lys-63 of Ub. Here, we present evidence that TIFA (TRAF-interacting protein with a forkhead-associated domain, also known as T2BP) activates IKK by promoting the oligomerization and Ub ligase activity of TRAF6. We show that recombinant TIFA protein, but not TRAF6-binding-defective mutant, can activate IKK in crude cytosolic extracts. Furthermore, TIFA activates IKK in an in vitro reconstitution system consisting of purified proteins, including TRAF6, the TAK1 kinase complex, and Ub-conjugating enzyme complex Ubc13-Uev1A. Interestingly, a fraction of recombinant TIFA protein exists as high-molecular-weight oligomers, and only these oligomeric forms of TIFA can activate IKK. Importantly, TIFA induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492226      PMCID: PMC524439          DOI: 10.1073/pnas.0404132101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling.

Authors:  J i Inoue; T Ishida; N Tsukamoto; N Kobayashi; A Naito; S Azuma; T Yamamoto
Journal:  Exp Cell Res       Date:  2000-01-10       Impact factor: 3.905

2.  Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain.

Authors:  L Deng; C Wang; E Spencer; L Yang; A Braun; J You; C Slaughter; C Pickart; Z J Chen
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

3.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling.

Authors:  M A Lomaga; W C Yeh; I Sarosi; G S Duncan; C Furlonger; A Ho; S Morony; C Capparelli; G Van; S Kaufman; A van der Heiden; A Itie; A Wakeham; W Khoo; T Sasaki; Z Cao; J M Penninger; C J Paige; D L Lacey; C R Dunstan; W J Boyle; D V Goeddel; T W Mak
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

4.  Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice.

Authors:  A Naito; S Azuma; S Tanaka; T Miyazaki; S Takaki; K Takatsu; K Nakao; K Nakamura; M Katsuki; T Yamamoto; J Inoue
Journal:  Genes Cells       Date:  1999-06       Impact factor: 1.891

5.  Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain.

Authors:  V Baud; Z G Liu; B Bennett; N Suzuki; Y Xia; M Karin
Journal:  Genes Dev       Date:  1999-05-15       Impact factor: 11.361

6.  Somatic mutagenesis studies of NF-kappa B signaling in human T cells: evidence for an essential role of IKK gamma in NF-kappa B activation by T-cell costimulatory signals and HTLV-I Tax protein.

Authors:  E W Harhaj; L Good; G Xiao; M Uhlik; M E Cvijic; I Rivera-Walsh; S C Sun
Journal:  Oncogene       Date:  2000-03-09       Impact factor: 9.867

7.  Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.

Authors:  T Ishida; S i Mizushima; S Azuma; N Kobayashi; T Tojo; K Suzuki; S Aizawa; T Watanabe; G Mosialos; E Kieff; T Yamamoto; J Inoue
Journal:  J Biol Chem       Date:  1996-11-15       Impact factor: 5.157

8.  NF-kappaB-inducing kinase activates IKK-alpha by phosphorylation of Ser-176.

Authors:  L Ling; Z Cao; D V Goeddel
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

9.  TRAF2 deficiency results in hyperactivity of certain TNFR1 signals and impairment of CD40-mediated responses.

Authors:  L T Nguyen; G S Duncan; C Mirtsos; M Ng; D E Speiser; A Shahinian; M W Marino; T W Mak; P S Ohashi; W C Yeh
Journal:  Immunity       Date:  1999-09       Impact factor: 31.745

10.  TRAF6 is a signal transducer for interleukin-1.

Authors:  Z Cao; J Xiong; M Takeuchi; T Kurama; D V Goeddel
Journal:  Nature       Date:  1996-10-03       Impact factor: 49.962

View more
  47 in total

Review 1.  Deciphering the complexity of Toll-like receptor signaling.

Authors:  Renato Ostuni; Ivan Zanoni; Francesca Granucci
Journal:  Cell Mol Life Sci       Date:  2010-07-31       Impact factor: 9.261

2.  Increased expression of TNF receptor-associated factor 6 after rat traumatic brain injury.

Authors:  Jian Chen; Xiujie Wu; Bai Shao; Wei Zhao; Wei Shi; Shuangwei Zhang; Lanchun Ni; Aiguo Shen
Journal:  Cell Mol Neurobiol       Date:  2010-11-12       Impact factor: 5.046

3.  Regulation of p53 localization and activity by Ubc13.

Authors:  Aaron Laine; Ivan Topisirovic; Dayong Zhai; John C Reed; Katherine L B Borden; Ze'ev Ronai
Journal:  Mol Cell Biol       Date:  2006-09-25       Impact factor: 4.272

4.  The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6.

Authors:  Shi Jiao; Zhen Zhang; Chuanchuan Li; Min Huang; Zhubing Shi; Yanyan Wang; Xiaomin Song; Heng Liu; Chunyang Li; Min Chen; Wenjia Wang; Yun Zhao; Zhengfan Jiang; Hongyan Wang; Catherine C L Wong; Chen Wang; Zhaocai Zhou
Journal:  Nat Immunol       Date:  2015-02-02       Impact factor: 25.606

Review 5.  TRAF6 activation in multiple myeloma: a potential therapeutic target.

Authors:  Hong Liu; Samantha Tamashiro; Stavroula Baritaki; Manuel Penichet; Youhua Yu; Haiming Chen; James Berenson; Benjamin Bonavida
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-03-21

6.  TIFA as a crucial mediator for NLRP3 inflammasome.

Authors:  Ting-Yang Lin; Tong-You Wade Wei; Shuai Li; Shen-Chih Wang; Ming He; Marcy Martin; Jiao Zhang; Tzu-Pin Shentu; Han Xiao; Jian Kang; Kuei-Chun Wang; Zhen Chen; Shu Chien; Ming-Daw Tsai; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2016-12-13       Impact factor: 11.205

Review 7.  A20: linking a complex regulator of ubiquitylation to immunity and human disease.

Authors:  Averil Ma; Barbara A Malynn
Journal:  Nat Rev Immunol       Date:  2012-10-12       Impact factor: 53.106

8.  TR-FRET-based high-throughput screening assay for identification of UBC13 inhibitors.

Authors:  Charitha Madiraju; Kate Welsh; Michael P Cuddy; Paulo H Godoi; Ian Pass; Tram Ngo; Stefan Vasile; Eduard A Sergienko; Paul Diaz; Shu-Ichi Matsuzawa; John C Reed
Journal:  J Biomol Screen       Date:  2011-10-27

Review 9.  A pervasive role of ubiquitin conjugation in activation and termination of IkappaB kinase pathways.

Authors:  Daniel Krappmann; Claus Scheidereit
Journal:  EMBO Rep       Date:  2005-04       Impact factor: 8.807

10.  ADP-heptose is a newly identified pathogen-associated molecular pattern of Shigella flexneri.

Authors:  Diego García-Weber; Anne-Sophie Dangeard; Johan Cornil; Linda Thai; Héloïse Rytter; Alla Zamyatina; Laurence A Mulard; Cécile Arrieumerlou
Journal:  EMBO Rep       Date:  2018-11-19       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.